Business Daily Media

Men's Weekly

.

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

  • Written by ACN Newswire - Press Releases

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

TOKYO, Jul 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep

Read more //?#

Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund

Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...

Global Thryv voices bring a sharper lens to International Women’s Day

Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...

AI curiosity fuels new wave of employee-led innovation in Australia

Leaders across Australia are asking themselves how they can ensure their employees get the most out of AI. We recently conducted research to help an...

Is your search bar your competitor’s best salesperson?

A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...

AIIMS Group and AdVisible merge

Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience     ...

Block's layoffs are a design win. Here's why

We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...